EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex
Background Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been shown to be effective and safe in the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC). The Everolimus For Fast Expanded aCcess in TSC SEGA (EFFECTS) study was de...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
8 August 2016
|
| In: |
BMC neurology
Year: 2016, Volume: 16 |
| ISSN: | 1471-2377 |
| DOI: | 10.1186/s12883-016-0658-4 |
| Online Access: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1186/s12883-016-0658-4 Verlag, kostenfrei, Volltext: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4976509/ 
|
| Author Notes: | Andras Fogarasi, Liesbeth De Waele, Gabriella Bartalini, Sergiusz Jozwiak, Nicola Laforgia, Helene Verhelst, Borivoj Petrak, Jean-Michel Pedespan, Olaf Witt, Ramon Castellana, Stefania Crippa, Gabriella Gislimberti and Zsuzsanna Gyorsok |
Search Result 1
EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex
BioMed Central; Springer 2016
Article (Journal)
Book/Monograph
Online Resource